BD to Present at UBS Genomics 2.0 and MedTech Innovations Summit

Rhea-AI Summary

BD (Becton, Dickinson and Company) (NYSE: BDX) announced management will present at the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021, at 4:00 p.m. PT. The presentation will be accessible via BD's investor relations website and available for replay for at least seven days post-event. Related materials will be posted before the event starts. BD is a prominent global medical technology company focused on advancing health through innovative technology, supporting healthcare providers, and addressing global health challenges.

FRANKLIN LAKES, N.J., July 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that management will be presenting at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 11, 2021, at 4:00 p.m. Pacific Time (PT)/7:00 p.m. Eastern Time (ET).

The webcast can be accessed through BD's investor relations website at www.bd.com/investors and will be available for replay for a minimum of seven days after the conference. Any related materials will be posted on the BD investor relations website no later than 7:00 a.m. ET on Wednesday August 11, 2021.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contacts:
Media	Investors
Troy Kirkpatrick	Kristen M. Stewart, CFA
VP, Public Relations	SVP, Strategy & Investor Relations
858.617.2361	201.847.5378
troy.kirkpatrick@bd.com	kristen.stewart@bd.com

 

 

View original content:https://www.prnewswire.com/news-releases/bd-to-present-at-ubs-genomics-2-0-and-medtech-innovations-summit-301344768.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

When is BD's presentation at the UBS Genomics 2.0 and MedTech Innovations Summit?

BD's presentation is scheduled for August 11, 2021, at 4:00 p.m. PT.

How can I access BD's presentation at the UBS Summit?

The presentation can be accessed through BD's investor relations website.

How long will the BD presentation be available for replay?

The presentation will be available for replay for a minimum of seven days after the conference.

What is the stock symbol for Becton, Dickinson and Company?

The stock symbol for Becton, Dickinson and Company is BDX.

What is the focus of BD as a company?

BD focuses on advancing health through medical discovery, diagnostics, and care delivery.